PolyPid (NASDAQ:PYPD) Releases Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) posted its earnings results on Wednesday. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07), Zacks reports.

Here are the key takeaways from PolyPid’s conference call:

• PolyPid reported positive SHIELD II Phase 3 results for D-PLEX100, meeting the primary and key secondary endpoints and showing a meaningful reduction in surgical site infections; the FDA gave written pre‑NDA feedback supporting a rolling NDA and said the existing clinical data appears adequate for submission.
• The company expects to begin a rolling NDA submission by the end of Q1 2026 and, with Fast Track/Breakthrough designations, anticipates an accelerated review timeline (targeting a ~6‑month priority review).
• PolyPid is in advanced U.S. partnership discussions with hospital‑focused commercial partners and is ramping commercialization readiness—KOL engagement, health‑economics work, packaging/branding and market access planning are underway to support a rapid post‑approval launch.
• As of Dec 31, 2025 the company held $12.9M in cash (plus $3.7M from subsequent warrant exercises) and believes runway extends into H2 2026, indicating a near‑term need to secure additional financing or partnership revenue that could dilute shareholders or pressure the stock.
• Management formally introduced Kynatrix as a next‑generation delivery platform and is advancing a preclinical ultra long‑acting GLP‑1 program (~60‑day release), a longer‑term opportunity while D‑PLEX100 remains the immediate commercial focus.

PolyPid Stock Performance

Shares of PYPD stock traded down $0.12 on Thursday, hitting $4.56. The stock had a trading volume of 6,883 shares, compared to its average volume of 73,500. The stock’s 50 day moving average is $4.35 and its 200-day moving average is $3.80. The firm has a market capitalization of $72.43 million, a price-to-earnings ratio of -1.53 and a beta of 1.52. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12.

Analyst Ratings Changes

PYPD has been the subject of a number of recent research reports. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Roth Mkm decreased their price target on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.25.

More PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright issued a bullish outlook, reaffirming a “Buy” and a $13 price target while raising long‑term earnings models (FY2028 to $0.21 and FY2030 to $4.02), implying substantial upside versus the current stock level. (No direct link provided)
• Positive Sentiment: Corporate update and earnings call highlighted that PolyPid is in advanced-stage U.S. partnership discussions for D‑PLEX₁₀₀ and flagged a material 2026 commercial catalyst, which could re-rate the stock if deals materialize. GlobeNewswire: Corporate Update
• Neutral Sentiment: Short interest rose ~44.8% in January (to ~27,918 shares) but remains a very small portion of float (~0.2%), so the short position currently presents limited near-term pressure given daily volume. (No direct link provided)
• Negative Sentiment: Q4 2025 results missed consensus: PolyPid reported EPS of ($0.41) versus consensus ($0.34), underscoring ongoing quarterly losses and supporting near-term downside risk until revenue or partnership milestones are secured. MarketBeat: Earnings and Call

Institutional Inflows and Outflows

An institutional investor recently raised its position in PolyPid stock. BNP Paribas Financial Markets lifted its stake in shares of PolyPid Ltd. (NASDAQ:PYPD) by 56.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,734 shares of the company’s stock after acquiring an additional 3,500 shares during the quarter. BNP Paribas Financial Markets owned 0.06% of PolyPid worth $32,000 at the end of the most recent reporting period. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.